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A B S T R A C T
Objectives: Gamma-Amiobutyric acid (GABA) is a primary inhibitory neurotransmitter that facilitates neural
oscillations that coordinate neural activity between brain networks to facilitate cognition. The present magnetic
resonance spectroscopy (MRS) study tests the hypothesis that GABAergic facilitation of working memory is
disrupted in people with schizophrenia (PSZ).
Methods: 51 healthy participants and 40 PSZ from the UC Davis Early Psychosis Program performed an item and
temporal order working memory (WM) task and underwent resting MRS to measure GABA and glutamate
concentrations in dorsolateral prefrontal (DLPFC) and anterior cingulate (ACC) regions of interest. MRS was
acquired on a 3 Tesla Siemens scanner and GABA and glutamate concentrations were referenced to creatine.
Percent correct on the WM task indexed performance and correlation coeﬃcients examined GABAergic or
Glutamatergic facilitation of WM, with Fisher's Z transformation testing for group diﬀerences.
Results: There were no group diﬀerences in GABA or glutamate concentrations, but WM correlations were re-
versed between groups. In patients, higher DLPFC GABA was associated with worse rather than better WM
performance. This pattern was not observed for glutamate or in the ACC. Although under-powered, there was no
indication of medication eﬀects.
Conclusions and Relevance: Results cannot be explained by group diﬀerences in DLPFC GABA or glutamate
concentrations but, instead, indicate that schizophrenia disrupts the GABAergic facilitation of WM seen in
healthy individuals. Results appear to parallel post mortem ﬁndings in suggesting that schizophrenia alters the
distribution of diﬀerent classes of GABAergic interneurons rather than producing a general deﬁcit across the
total population of neurons.
1. Introduction
Gamma-Aminobutyric acid (GABA) is the primary inhibitory neu-
rotransmitter in the brain, and GABA-ergic regulation of neural excit-
ability appears to play a critical role in coordination of activity within
and between local brain circuits that support high level cognition
(Whittington et al., 1995; Vida et al., 2006). Magnetic resonance
spectroscopy (MRS) has emerged as a valuable tool for noninvasively
investigating the relationship between GABA and cognition. For ex-
ample, Porges et al. (2017) found that higher GABA concentrations in
frontal but not in posterior cortex predicted better performance on a
summary cognitive measure in healthy older adults. In our own la-
boratory, Yoon and colleagues Yoon et al. (2016) found that higher
GABA concentrations in the dorsolateral prefrontal cortex (DLPFC)
were correlated with better working memory (WM performance at high
load relative to low load task conditions in healthy subjects. Supporting
speciﬁcity to DLPFC and WM, these associations were not observed in
the primary visual cortex, or for other task conditions. These MRS
ﬁndings converge with the earlier work of Patricia Goldman-Rakic
(Rao et al., 2000), who used neural recordings in non-human primates
to demonstrate that prefrontal GABAergic interneurons regulate the
ﬁring of excitatory glutamatergic neurons in the PFC during WM delay
periods.
People with schizophrenia show signiﬁcant deﬁcits in cognition,
and they are particularly impaired at WM tasks that place heavy de-
mands on cognitive control processes dependent on the DLPFC
(Barch et al., 2003; Lesh et al., 2011). Given the basic research de-
scribed above, there is reason to suspect that WM deﬁcits in
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schizophrenia might reﬂect disruption of GABAergic function. Indeed,
one of the most consistent post-mortem ﬁndings (Hyde et al., 2011) in
schizophrenia research is deﬁcient GABA synthesis, due to reduced
transcription of the GAD67 gene in speciﬁc subclasses of interneurons
in the DLPFC (Akbarian et al., 1995; Volk et al., 2001), anterior cin-
gulate gyrus (ACC) (Woo et al., 2007), and hippocampus (Benes et al.,
2007). This deﬁcit in GAD67 mRNA is most consistently found in a
subset of parvalbumin containing GABAergic basket cell inter-neurons,
leading to a reduced production of GABA in the cortex of people with
schizophrenia (Lewis 2014). These combined human and animal studies
make GABAergic inhibition a potential therapeutic target
(Vinkers et al., 2010) for improving well-documented WM deﬁcits
(Barch and Sheﬃeld 2014) in people with schizophrenia.
Despite the consistency of the post-mortem ﬁndings described
above, it has been diﬃcult to establish a reproducible in vivo pattern of
reduced GABA concentrations in patients relative to controls using
MRS. For example, two recent meta-analyses (Egerton et al., 2017;
Iwata et al., 2018) failed to ﬁnd any group diﬀerences in GABA con-
centrations at a meta-analytic level. Although several MRS studies
found GABA reductions in patients (Goto et al., 2009; Yoon et al., 2010;
Kelemen et al., 2013; Wang et al., 2019), an equal number found either
no group diﬀerences (Tayoshi et al., 2010; Kegeles et al., 2012;
Chen et al., 2014), or increased MRS GABA concentrations in patients
relative to controls (Ongur et al., 2010; Rowland et al., 2013). Ex-
planations for this lack of convergence between post-mortem and MRS
ﬁndings include the often-greater illness progression and lifetime
medication exposure of post-mortem individuals (Szulc et al., 2013;
Brandt et al., 2016), although there have also been failures to ﬁnd
diﬀerences between medicated and un-medicated patients (Wood et al.,
2008; Kegeles et al., 2012). An alternative explanation is that GA-
BAergic function in schizophrenia may be speciﬁcally disrupted in
particular brain regions like the DLPFC—regions that are known to
contribute to the kinds of cognitive processes that are impaired in
schizophrenia.
The goal of this study is to examine the impact of schizophrenia on
the association between DLPFC GABA and WM performance using
single-voxel proton MRS. Data were also obtained in an ACC ROI as a
control region, and with a conventional PRESS acquisition to obtain
glutamate concentrations (Glu) to provide tissue measurements of both
excitatory and inhibitory neurotransmitters. To examine these asso-
ciations, we utilized a WM task that has been shown to elicit DLPFC
activity (Roberts et al., 2018) and neural oscillations that depend on
inhibitory neurotransmission in PFC (Hsieh et al., 2011). We chose this
task because our previous functional MRI research (Ragland et al.,
2012; Ragland et al., 2015) found that people with schizophrenia had a
disproportionate deﬁcit in relational versus item-speciﬁc working and
long-term memory that was accompanied by a reduction in DLPFC
activation for relational but not item-speciﬁc task conditions. We pre-
dicted that patients would show a regionally speciﬁc pattern of dis-
rupted GABAergic facilitation of WM in a DLPFC but not in an ACC ROI.
Additionally, our paradigm allowed us to separately test relationships
between GABA and a WM task that involved maintenance of temporal
order information and a WM task that required maintenance of detailed
visual information about items.
2. Methods
2.1. Participants
Data are reported on 51 controls and 40 patients with schizo-
phrenia. Patients were early in their illness (within 5 years of illness
onset). Groups were matched for age, gender, handedness and parental
education (Table 1). As expected, participant education and an estimate
of premorbid intellectual ability (WTAR) was lower in patients. All but
9 patients were receiving medication (all atypical antipsychotics) and
were clinically stable with mild to moderate symptomatology (Table 1).
Subjects were excluded for substance dependence or a positive urine
drug screen, a neurological illness, head trauma leading to un-
consciousness, low IQ (WAIS-R Total score < 70), corrected vision that
does not achieve 20/30, pregnancy, ferrous metal in any part of body,
serious medical conditions, and claustrophobia. Data collection began
after participants provided written informed consent following In-
stitutional Review Board approval.
2.2. Procedures
After informed consent, each participant performed a resting-state
(eyes open) MRS study and a Temporal-Order and Item Maintenance
WM paradigm (Hsieh et al., 2011) that was administered separately
during EEG, which will be reported in a separate manuscript. Studies
were performed within 2-weeks of each other, and patients did not
experience any changes in medication or clinical status between the
two sessions.
2.3. MRS acquisition
Participants were scanned with proton MRS using a Siemens TIM
Trio 3T MRI system with a 32-channel head coil. An anatomical MRI
was acquired and used for placement of DLPFC and ACC voxels (Fig. 1).
As in our previous study (Yoon et al., 2016), the DLPFC voxel was
placed in the left middle frontal gyrus over Brodmann areas 9 and 46,
and angled parallel to the brain surface, with dimensions of
30 mm x 15 mm x 35 mm (volume 15.75 cm3). The ACC voxel was un-
rotated and placed midline over Brodmann area 32, approximately
1 cm above the upper extent of the body of the lateral ventricles, with
the posterior extent abutting the corpus callosum, and voxel dimensions
of 30 mm x 25 mm x 25 mm (volume 18.75 cm3).
Table 1.
Participant demographics.
Healthy control
group (n =51)
People with
schizophrenia (n =40)
p-value
Mean SD Mean SD
Age (years) 24.2 4.7 23.5 4.6 ns
Gender (% male) 67 70 ns
Handedness (%
right)
94 95 ns
WTAR 41.5 5.5 38.3 8.3 p < .05
Education (years) 15.0 2.1 13.6 1.8 p < .005
Parental Education
(years)
13.9 2.4 14.6 2.7 ns
SANS (total) – – 20.4 12.5 –
SAPS (total) – – 6.0 8.0 –
BPRS (total) – – 37.5 8.3 –
Note: ns = no signiﬁcant group diﬀerence at p<.05, two-tailed;
WTAR = Wechsler Test of Adult Reading; Parental Education = average
number of years across parents
Fig. 1. Placement of DLPFC (left) and ACC voxels (right).
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After voxel placement, we acquired GABA measurements using a
Mescher-Garwood point resolved spectroscopy (MEGA-PRESS) GABA
editing sequence with water suppression (Mescher et al., 1998;
Mullins et al., 2014). This single voxel J-diﬀerence spectral editing
sequence enables the GABA resonance at 2.99 ppm to be distinguished
from the overlapping creatine singlet, as well as removing other re-
sonances. This is achieved through the subtraction of two in-
dependently acquired spectra that have GABA J-coupled resonances of
opposite polarity at 2.99 ppm. MRS spectra were acquired with the
following parameters: TR/TE: 1500/68; acquisition duration: 852 ms;
16 step EXOR phase cycling; data points: 1024; receiver bandwidth:
1200 Hz; edit pulse on resonance frequency: 1.9 ppm; edit pulse oﬀ
resonance frequency: 7.5 ppm; delta frequency: 1.7 ppm; edit pulse
bandwidth: 45 Hz. Acquisitions in which the spectral editing pulse was
applied on resonance were interleaved with those in which the pulse
was applied oﬀ resonance for a total of 144 acquisitions in each of four
consecutive 3.6 min subscans in the 2 brain regions studied (DLPFC and
ACC). The water frequency was adjusted before each 3.6 min scan. The
subscans were later combined oﬀ-line. GABA content measured by this
method includes signal from macromolecules and homocarnosine that
coedit with GABA. Total GABA acquisition time for each voxel location
was 14.4 min, and the order of DLPFC versus ACC voxel acquisition was
randomized across subjects. To measure DLPFC glutamate content, we
also obtained a PRESS acquisition from the DLPFC voxel using the
following parameters: TR/TE = 1500/80 ms, delta fre-
quency = −1.7 ppm, NEX = 160, duration = 4.0 min.
2.4. Working memory assessment
The Temporal-Order and Item Maintenance task (Hsieh et al., 2011)
is illustrated in Fig. 2. On each trial, subjects ﬁrst see an instruction
word, either “ITEM” or “ORDER”, followed by a memory set of four
sequentially presented kaleidoscopic (fractal) images. Following a 3-s
retention delay, a test probe is shown. On “order” trials, the probe
consists of two fractals from the previous sequence, and subjects were
asked to make a left-handed button-press if the object on the left was
seen ﬁrst, and a right-handed button press if the object on the right was
seen ﬁrst. On “item” trials, the test probe consisted of one previously
presented fractal along with another fractal that was never presented,
and subjects were instructed to make a left handed button-press if the
object on the left is old, and a right handed response if the object on the
right is old. During each run, blocks of 10 order trials and 10 item trials
were presented in a counter-balanced order, and the sequence was re-
peated for 10 runs, requiring about 60 min to complete. Participants
were given a practice task to ensure comprehension and instructed to
respond as quickly and accurately as possible.
2.5. Data analysis and hypothesis testing
2.5.1. MRS processing
Using jMRUI 4.0 software, all pairs of on- and oﬀ-resonance spectra
from the MEGA-PRESS acquisitions were phase aligned with reference
to creatine, zero ﬁlled to 4096, apodized with a 4 Hz Gaussian ﬁlter,
and frequency aligned to creatine (Cr) at 3.02 ppm. Diﬀerence spectra
were processed in parallel fashion, with the phase correction derived
from each pair of on and oﬀ spectra applied to each diﬀerence spec-
trum. Peak integration was used to quantify GABA (2.99 ± 0.12 ppm)
in the diﬀerence spectra and Cr (3.02 ± 0.09 ppm) in the summed on
and oﬀ spectra, as described previously (Yoon et al., 2010). The ratio of
GABA/Cr signal averaged across all subscans in each brain region for
each subject was used for hypothesis testing. Normalizing to Cr reduces
intersubject variance attributable to diﬀerences in global signal
strength and CSF fraction within the voxel and has been shown to yield
reliable GABA values (Greenhouse et al., 2016). A large, multicenter
study has shown that measures of GABA normalized to creatine were
reliable and exhibited strong agreement across sites (Mikkelsen et al.,
2017). All ﬁnal diﬀerence spectra were inspected for water or lipid
contamination.
PRESS spectra were analyzed with LCModel software (v6.3 1-L)
(Provencher 2001). Metabolite values were ﬁt using an analysis
window from 4.0 to 1.7 ppm and a simulated basis set provided with
LCModel that included the following metabolites: glutamate, gluta-
mine, glutathione, creatine, phosphocreatine, n-acetylaspartate, n-
acetylaspartylglutamate, phosphocholine, glycerophosphorylcholine,
myo-inositol, scyllo-inositol, aspartate, taurine, GABA, and glucose.
Glutamate signal (Glu) was normalized to the LCModel ﬁts for creatine
plus phosphocreatine (Cr). The Glu/Cr ratio was used for hypothesis
testing. All GABA/Cr and Glu/Cr distributions were inspected for ex-
treme outliers, deﬁned as a modiﬁed Z score > 4.0 by the method of
Iglewicz and Hoaglin (Iglewicz and Hoaglin 1993).
Data quality assessment (QA) was performed by examining signal to
noise (SNR) and spectroscopic line width resolution (FWHM) for both
the PRESS and the MEGA-PRESS acquisitions. In addition, the
Cramer–Rao lower bound (CRLB; Kreis 2004) provided an index of the
reliability of the glutamate estimates from the PRESS spectra. As can be
seen in Table 2, QA metrics were excellent across both groups and re-
gions.
2.5.2. Working memory processing
Percent correct performance (out of 100 item and 100 order trials)
Fig. 2. Illustration of Temporal Order and Item Maintenance Task.
Table 2
Mean (± SD) Quality Assessment (QA) metrics for MRS acquisitions.
SNRa FWHM (ppm)b CRLB (glu only)c
Oﬀ-res MPRESS DLPFCd
Patients 39.0 (4.1) 0.036 (0.007)
Controls 39.3 (4.8) 0.038 (0.010)
Oﬀ-res MPRESS ACCe
Patients 36.9 (5.9) 0.040 (0.013)
Controls 37.0 (6.0) 0.042 (0.013)
PRESS DLPFCf
Patients 33.2 (3.7) 0.041 (0.006) 5.7% (0.7)
Controls 33.0 (4.8) 0.042 (0.008) 5.8% (0.7)
Abbreviations:.
a SNR = signal to noise ratio.
b FWHM = full width half max line width spectral resolution.
c CRLB = Cramer–Rao lower bound.
d Oﬀ-res MPRESS DLPFC = oﬀ-resonance Mega-PRESS GABA acquisition in
dorsolateral prefrontal cortex voxel.
e Oﬀ-res MPRESS ACC = oﬀ-resonance Mega-PRESS GABA acquisition in
anterior cingulate cortex voxel.
f PRESS DLPFC = PRESS glutamate acquisition in dorsolateral prefrontal
cortex voxel.
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was calculated separately for each task condition to provide a measure
of WM accuracy. Data were inspected to insure that all participants
were performing above chance (i.e., > 50% accuracy), and no parti-
cipants had to be excluded for below-chance performance. Percent
correct performance was entered into a two (patient, control) by two
(item, order) repeated-measures analysis of variance (ANOVA).
Associations with MRS GABA and Glutamate concentrations were ex-
amined with separate Pearson Product Moment correlations, and a
Fisher's Z transformation was performed to test for signiﬁcant group
diﬀerences in correlational results. Signiﬁcance level was set at p< .05,
two-tailed for all analyses.
3. Results
3.1. Gray and white matter concentrations
Given potential anatomical diﬀerences between groups, we ﬁrst
examined gray and white matter concentrations in DLPFC and ACC
MRS voxels to rule-out any group diﬀerences that could inﬂuence MRS
ﬁndings. Gray and white matter proportions were estimated for each
subject and each voxel utilizing their segmented MPRAGE image, with
MRS voxels applied as a mask. T-test analyses did not reveal any group
diﬀerences in percent gray (p-value =.17) or white matter (p-
value =.26) in the ACC and also failed to reveal any group diﬀerences
in the DLPFC for either gray (p-value =.19) or white matter (p-
value =.28).
3.2. GABA
DLPFC GABA data were excluded for two subjects: one control
subject whose spectra were excluded due to excessive lipid con-
tamination, and one patient whose GABA/Cr value was an extreme
outlier (modiﬁed Z score > 4). MRS spectra for the remaining 50
control subjects and 39 patients are illustrated in Fig. 3. Group com-
parisons revealed that DLPFC GABA/Cr values were similar for patients
(0.147 ± 0.013) and controls (0.145 ± 0.011; p-value =.62) and did
not diﬀer between medicated (0.147 ± 0.013) and un-medicated pa-
tients (0.144 ± 0.014; p-value =.54). Because analysis of medication
eﬀects was under-powered, we also examined eﬀect sizes, which re-
vealed small diﬀerences in DLPFC GABA/Cr ratios between medicated
and unmedicated patients (Cohen's d= 0.22). ACC GABA data were not
obtained in two control subjects and two patients. In the remaining 49
control subjects and 38 patients, ACC GABA/Cr values were similar for
patients (0.156 ± 0.022) and controls (0.151 ± 0.024; p-value =.28)
and did not diﬀer between medicated (0.151 ± 0.013) and un-medi-
cated patients (0.154 ± 0.015; p-value =.64; Cohen's d = 0.21).
3.3. Glutamate
DLPFC Glu/Cr values were excluded for two control subjects and
two patients whose PRESS spectra did not meet our LCModel FWHM
and SNR inclusion thresholds (≤ 0.063 ppm and≥ 20 respectively). In
the remaining 49 control subjects and 38 patients, FWHM values
ranged from 0.028 to 0.063 ppm (mean = 0.042) and SNR values
ranged from 24 to 43 (mean = 33.0). In these subjects, DLPFC Glu/Cr
values were similar for patients (0.894 ± 0.104) and controls
(0.906 + +0.091; p-value =.54) and did not signiﬁcantly diﬀer be-
tween medicated (0.892 ± 0.093) and unmedicated patients
(0.900 ± 0.134; p-value =.82; Cohen's d = 0.07).
3.4. Working memory
Accuracy was generally higher on Item (80 ± 11) than on Order
(75 ± 14) trials [F(1,86) =14.7, p < .001], and overall accuracy was
lower for patients than controls [F(1,86) =30.0, p < .0001] on both
Item (73 ± 12 vs. 84 ± 8) and Order tasks (67 ± 14 vs. 80 ± 10).
There was no eﬀect of medication on WM performance (t-values <1.0,
p > .05; Cohen's d = 0.23).
3.5. GABA correlations with working memory
For healthy controls, higher DLPFC GABA/Cr concentrations were
correlated with better WM on both Item (r-value =0.29, p < .05;
Fig. 4A) and Order tasks (r-value =0.29, p < .05; Fig. 4B). Conversely,
higher GABA/Cr values correlated with worse WM in patients for the
Item task (r-value =−0.38, p < .005), with a similar trend evident for
the Order task (r-value =−0.27, p =.09). Crucially, these correlations
diﬀered between groups for both Item (Fisher's Z=3.15, p< .005) and
Order conditions (Fisher's Z =2.60, p < .005), with no medication
eﬀect (all Fisher's Z < 0.1). There were no signiﬁcant correlations be-
tween WM performance and either ACC GABA/Cr or DLPFC Glu/Cr
values.
4. Discussion
The goal of this study was to examine relationships between pre-
frontal GABA levels and WM performance in schizophrenia. We re-
plicated and extended our previous ﬁndings (Yoon et al., 2016)
showing that higher GABA concentrations in the DLPFC are associated
with better WM performance in healthy participants. Our results ad-
ditionally show that healthy controls with higher DLPFC GABA were
better able to maintain object and temporal order information in WM.
This facilitation eﬀect appeared to be both regionally speciﬁc – as it was
not observed in the anterior cingulate, and speciﬁc to inhibitory
(GABA) and not excitatory (glutamate) transmitter levels. Our predic-
tion of disrupted GABAergic modulation of WM in people with schi-
zophrenia was also supported. Patients produced negative correlations
between DLPFC GABA and WM performance that were signiﬁcantly
diﬀerent that the positive correlations evidenced by healthy controls.
Moreover, these results did not appear to be secondary to group dif-
ferences in gray or white matter tissue concentrations, were not af-
fected by medication status and were, again, speciﬁc to the DLPFC
Fig. 3. Creatine-normalized grand mean diﬀerence spectra for people with
schizophrenia (top tracing) and healthy controls (bottom tracing). The edited
resonances for GABA, glutamate and Glx (glutamate plus glutamine) and the
inverted NAA peak are indicated.
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rather than the ACC and to GABA rather than glutamate.
Although our results revealed signiﬁcant disruption of the re-
lationship between DLPFC GABA levels and WM performance in schi-
zophrenia we found no evidence of overall GABA deﬁcits in patients
either for DLPFC or ACC. Previous meta-analyses of the MRS literature
have not shown reliable group diﬀerences in MRS GABA concentrations
across many regions of the brain (medial and dorsolateral PFC; tem-
poral, parietal and occipital cortex; basal ganglia, hippocampus and
thalamus) (Egerton et al., 2017; Iwata et al., 2018). Previous MRS
studies have not consistently found signiﬁcant medication eﬀects
(Wood et al., 2008; Kegeles et al., 2012) and, in our sample, GABA
concentrations values in DLPFC and ACC were almost identical across
medicated and unmedicated patients, with small eﬀect sizes of medi-
cation status. Conversely, results from a recent positron emission to-
mography (PET) study converged with post-mortem ﬁndings and found
that antipsychotic treatment appears to normalize GABA signaling that
is typically reduced in patients prior to treatment (Frankle et al., 2015).
The consistency of post-mortem ﬁndings and inconsistency of MRS
GABA results deserves further scrutiny as our unmedicated sample was
very small.
As previously noted, post-mortem analyses reveal that GAD67 is
reduced only in sub-populations of GABAergic inter-neurons in people
with schizophrenia (Akbarian et al., 1995; Lewis 2012), whereas MRS
measures GABA in all intra- and extra-cellular compartments across all
populations of brain cells within the ROI. This global MRS value may,
therefore, reduce sensitivity to group diﬀerences in a smaller popula-
tion of parvalbumin containing inter-neurons. The absence of group
diﬀerences in the current study contrasts with consistent prior reports
of a schizophrenia-related reduction in GABA concentration in the early
visual cortex (Yoon et al., 2010; Kelemen et al., 2013). This may reﬂect
a regional diﬀerence in how the disease process aﬀects global GABA
levels as measurable with MRS. For example, post-mortem studies show
a normal gradient in GABA neurotransmission, with a decrease in GABA
transcript levels from the visual cortex to the DLPFC (Hoftman et al.,
2018). It is also possible that the greater signal-to-noise (SNR) in the
posterior cortex where the skull is in direct contact with MRI head coil
leads to better detection of group diﬀerences in early visual cortex. Use
of higher-ﬁeld scanners increases SNR and may also improve detection
of group diﬀerences. However, recent 7 Tesla studies have been both
successful (Marsman et al., 2014; Wang et al., 2019) and unsuccessful
(Reid et al., 2018) in detecting reduced GABA concentrations between
psychosis patients and healthy controls.
Fig. 4. Scatter plots of correlations between DLPFC GABA/Cr ratios (y-axis) and percent correct working memory performance for Item (1A) and Order task
conditions (1B). Healthy controls presented on the left (blue symbols) and people with schizophrenia on right (red symbols). (For interpretation of the references to
color in this ﬁgure legend, the reader is referred to the web version of this article.)
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4.1. Conclusions
In the present study, in a large sample of people with schizophrenia,
we found no evidence for an overall change in DLPFC GABA or gluta-
mate concentrations in either the DLPFC or the ACC. Instead, our results
showed signiﬁcant group diﬀerences in the relationship between GABA
levels and WM performance. Unlike controls, higher GABA/Cr ratios
were correlated with worse rather than better cognitive performance in
the patient sample. Previous MRS studies have also found inverse cor-
relations between cognition and GABA levels (Marsman et al., 2014;
Reid et al., 2018). However, Rowland et al. (2013) found that ACC
GABA was positively correlated with a coding test of attention in a
pooled sample of schizophrenia patients and healthy volunteers. Recent
developments in performing functional task-based MRS studies
(Jelen et al., 2018) may help to improve understanding of these brain-
behavior relationships.
Given that overall prefrontal GABA concentrations were relatively
normal in the early psychosis sample, altered relationships between
GABA levels and cognition could reﬂect diﬀerences in the distribution
of GABA across diﬀerent classes of GABAergic interneurons, which
might, in turn, lead to alterations in neural activity in circuitry asso-
ciated with WM. Changes in the relative functioning of parvalbumin-
containing Interneurons (Lewis 2012) and cholecystokinin expressing
(CCKb) basket cells (Hartwich et al., 2009), might produce network-
level imbalances that alter interactions between DLPFC and posterior
cortical regions, and the hippocampus.
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